Avion Pharmaceuticals, LLC., announces participation in the NPWH Health Meeting

Avion Pharmaceuticals, a specialty pharmaceutical company, announces their participation as an exhibitor at the annual Nurse Practitioner in Women’s Health Meeting. The meeting is planned for October 10-13th, 2012 at the Ritz Carlton in Grande Lakes, Florida.

Featured at the meeting will be Avion’s newest addition to the prenatal vitamin family, Prenate Mini®. Prenate Mini from Avion Pharmaceuticals contains 1 mg of folic acid in the form of Quatrefolic®. Quatrefolic®, the fourth generation folate that is found in the Prenate® Vitamin Family, is the active form of folate that is beneficial to women, including the 50% with an impaired ability to break down folic acid.

“Avion is a proud to support women’s health initiatives and excited to partner with NPWH”, stated Mike Sullivan, Vice President of Sales and Marketing for Avion Pharmaceuticals. “We are looking forward to sharing the benefits of Prenate Mini® with the Nurse Practitioner community” and education for healthy pregnancies. In addition, we will continue to focus on the development of unique and innovative product solutions designed for today’s moms and babies.”

CEO Mark Pugh added, “Our research validates that 40% of Americans have trouble swallowing. Prenate Mini®’s small size offers a great solution to assist in patient compliance. Avion Pharmaceuticals is looking forward to sharing our newest innovation to support women’s health at the NPWH meeting”.

Our Avion Team! Mary Claire Kenworthy, Art Deas, Mike Sullivan, Jonathan Thomas, Karen Savage and Summer Hasan (l to r)


Jonathon Thomas and Summer Hasan Driving Prescriptions for Prenate Mini!!
Jonathon Thomas and Summer Hasan Driving Prescriptions for Prenate Mini!!


About Avion Pharmaceuticals, LLC

Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women’s Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.